Sutro Biopharma specializes in ADCs for oncology and shows promise with STRO-002 for ovarian cancer and collaborations with ...

NDAQ:SONN) Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors ...

The use of targeted therapy significantly improved ORR and PFS in patients with a long-term PFS benefit at one year and ...

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...

Shares closed at $21.15 on Sept. 19. The proposed offering announcement came a day after Xencor announced four new autoimmune ...

VINING – After being injured in a serious car accident earlier this year, Vining residents Arlo and Nancy Cibula recently ...

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease ...

In a recent study published in Nature Communications, researchers developed a microstructure-sensitive model to examine the ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...